CD82 and Familial prostate cancer: A recent study suggests that CD82 may suppress epithelial to mesenchymal transition (EMT) in prostate cancer cells on fibronectin matrix by laterally interacting with α3β1 and α5β1 integrins to repress integrin signaling [36], inhibiting cell migration and invasion.